← Back to Search

Glucan Synthase Inhibitor

SCY-078 for Invasive Candidiasis (CARES Trial)

Phase 3
Waitlist Available
Research Sponsored by Scynexis, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 42 and day 84
Awards & highlights

CARES Trial Summary

This trial is testing a new drug to treat Candida auris, a dangerous infection. The new drug is SCY-078 and it will be given to patients to see if it is effective, safe, and tolerated.

Eligible Conditions
  • Invasive Candidiasis
  • Candida Blood Infection

CARES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 42 and day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 42 and day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy as measured by the percentage of subjects with global success at end of treatment
Secondary outcome measures
Number of participants with Discontinuations due to Adverse Events (Safety)
Number of participants with treatment-related Adverse Events (Safety)
Recurrence of Baseline Fungal Infection (Efficacy)
+1 more

Side effects data

From 2018 Phase 2 trial • 186 Patients • NCT03253094
47%
Diarrhoea
25%
Nausea
16%
Abdominal pain
9%
Headache
6%
Blood creatine phosphokinase increased
3%
Abdominal pain upper
3%
Dizziness
3%
Somnolence
3%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ibrexafungerp 750-mg
Ibrexafungerp 300-mg
Ibrexafungerp 450-mg
Ibrexafungerp 150-mg
Ibrexafungerp 300-mg D1 to D3
Fluconazole

CARES Trial Design

1Treatment groups
Experimental Treatment
Group I: SCY-078Experimental Treatment1 Intervention
SCY-078
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibrexafungerp
FDA approved

Find a Location

Who is running the clinical trial?

Scynexis, Inc.Lead Sponsor
17 Previous Clinical Trials
2,448 Total Patients Enrolled
David Angulo, MDStudy DirectorScynexis, Inc.
7 Previous Clinical Trials
1,160 Total Patients Enrolled
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top